Prolor Biotech developed unique technologies, including patented CTP technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins. In addition to its long-acting version of human growth hormone, which successfully completed clinical trials, PROLOR also developed long-acting versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity.
Prolor was acquired by OPKO on 2013 in a transaction valued at approximately $480 million.
OPKO signed a world-wide collaboration agreement with Pfizer Inc. for the development and commercialization of hGH-CTP.